[Skip to Content]
[Skip to Content Landing]
December 5, 1990

New Approaches for Inflammatory Bowel Disease

JAMA. 1990;264(21):2741. doi:10.1001/jama.1990.03450210036025

To the Editor. —  We have read Paul Cotton's excellent review article, "New Approaches May Aid Patients With Inflammatory Bowel Disease,"1 and we would like to report our preliminary results with interferon alpha-2a (Roferon-A/Roche) for treating children with severe, therapy-refractive inflammatory bowel disease: one girl with ulcerative colitis and two boys with Crohn's disease.The patients have received 3 million U of interferon alpha-2a subcutaneously three times a week for a period of 4 to 6 months. The treatment significantly ameliorated the clinical symptoms in all patients: urgency and bloody diarrhea, as well as abdominal pains after 4 weeks. The girl with ulcerative colitis is now in full remission with normal bowel movements and no bloody diarrhea and has a normal life-style. Both boys with Crohn's disease have gained weight, and their perianal fistulas have healed with their achievement of complete clinical and histological remission.The rationale for treating